EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy

Ya Liu, Tingting Xu, Hongyu Yang, Zhanwen Huang, Haoyuan Ding, Yu Zhang, Yue Chen

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8347-8357

DOI: 10.1007/s00259-026-08138-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.08.2026. Verfasst von Ya Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds, Positron-Emission Tomography, Octreotide. Die Arbeit nennt 24 Literaturangaben. Gefördert von: the Gansu Provincial Science and Technology Major Project, the National Key Research and Development Program (NKRDP) Project, the Scientific Research Project of Southwest Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the association between baseline NETPET score and prognosis in patients with neuroendocrine tumors (NETs) receiving [225Ac]Ac-DOTATATE therapy. METHODS: This retrospective study included patients with NETs treated with [225Ac]Ac-DOTATATE between November 2021 and March 2025. All patients underwent [18F]F-FDG and [68Ga]Ga-DOTATATE PET within one week before treatment. Up to 10 representative lesions per patient were selected for NETPET scoring. The primary endpoint was progression-free survival (PFS). The relationship between NETPET score and PFS was evaluated using Kaplan-Meier analysis and univariate/multivariate Cox proportional hazards models. RESULTS: Forty-eight patients were enrolled (P1: n = 14, P2-4: n = 22, P5: n = 12). The P1 group achieved significantly better PFS than the P2-4 and P5 groups (2-year PFS rates: 0.83 vs. 0.32 vs. 0.10; log-rank P 0.05). CONCLUSION: The NETPET score was independently associated with progression-free survival and may serve as a potential imaging biomarker for pretreatment risk stratification in NET patients receiving [225Ac]Ac-DOTATATE therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsPositron-Emission TomographyOctreotideHumansFemalePrognosisRetrospective StudiesMaleMiddle AgedAgedAdultRadioactive Tracers

Stichwörter der Autor:innen

BiomarkerNETPETNeuroendocrine tumors[225Ac]Ac-DOTATATE

Substanzen

Organometallic CompoundsOctreotideRadioactive Tracersgallium Ga 68 dotatate

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
  • Department of Nuclear Medicine, Laboratory of Sichuan Province Institute of Nuclear Medicine, Affiliated Hospital of Southwest Medical University Nuclear Medicine and Theranostics Key, Southwest Medical University , No…
  • Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Institute of Nuclear Medicine, Southwest Medical Univer…
  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. 315699969@qq.com.
  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. zhangyu309@126.com.
  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. chenyue5523@126.com.

Förderung

  • the Gansu Provincial Science and Technology Major Project
  • the National Key Research and Development Program (NKRDP) Project
  • the Scientific Research Project of Southwest Medical University

Zitieren

APA

Liu, Y., Xu, T., Yang, H., Huang, Z., Ding, H., Zhang, Y., & Chen, Y. (2026). Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8347-8357. https://doi.org/10.1007/s00259-026-08138-0

Vancouver

Liu Y, Xu T, Yang H, Huang Z, Ding H, Zhang Y, et al. Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8347-8357. doi:10.1007/s00259-026-08138-0

BibTeX
@article{Liu2026,
  author = {Liu, Ya and Xu, Tingting and Yang, Hongyu and Huang, Zhanwen and Ding, Haoyuan and Zhang, Yu and Chen, Yue},
  title = {Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8347--8357},
  doi = {10.1007/s00259-026-08138-0}
}
Kostenlos starten →